Competitive Intelligence In Breast Cancer: Tracking The Evolving HR+ HER2-Ve Breast Cancer ...
In-Depth Market Assessment : A detailed market analysis of the HR+ HER2-negative Breast Cancer domain was included, covering pipeline insights and the projected launch timelines of emerging therapies.
Targeted Oncology19 小时
T-DXd Reevaluated in HER2-Low/HER2-Negative Breast Cancer After New Trials
During a Case-Based Roundtable event, Laura Huppert, MD, discussed data and considerations around using T-DXd in breast ...